Literature DB >> 28129697

Rituximab-induced Crohn's disease.

Poornima Varma1, Julianne Falconer2, Ahmad Aga3, H Miles Prince2,4, Stephen Pianko1.   

Abstract

The use of rituximab has significantly improved outcomes in patients with haematological malignancies and autoimmune disease. There are reports of rituximab-associated ulcerative colitis; however, we report for the first time, two cases of rituximab-induced Crohn's disease in elderly patients treated for lymphoma. Both patients had evidence of inflammation, ulceration, and granulomas consistent with Crohn's disease, and responded well to immunosuppression. The association of rituximab and ileocolitis suggests a protective effect of CD20 + lymphocytes in the gut, and implicates their depletion to the development and exacerbation of inflammatory bowel disease.

Entities:  

Keywords:  Crohn’s disease; Rituximab; anti-CD20 therapy; inflammatory bowel disease; lymphoma

Mesh：

Substances：

Year:  2017        PMID： 28129697     DOI： 10.1080/00365521.2017.1280530

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN： 0036-5521            Impact factor:   2.423


  9 in total

1.  Efficient long-term depletion of CD20+ B cells by rituximab does not affect gut-resident plasma cells.

Authors:  Mathieu Uzzan; Huaibin M Ko; Adam K Rosenstein; Kamron Pourmand; Jean-Frederic Colombel; Saurabh Mehandru
Journal:  Ann N Y Acad Sci       Date:  2017-12-31       Impact factor: 5.691

Review 2.  [Gastrointestinal tract diseases induced by medications].

Authors:  H Bläker
Journal:  Pathologe       Date:  2018-11       Impact factor: 1.011

Review 3.  Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?

Authors:  Naoimh Herlihy; Roger Feakins
Journal:  United European Gastroenterol J       Date:  2022-05-28       Impact factor: 6.866

Review 4.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

Review 5.  Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.

Authors:  Si-Nan Lin; Ren Mao; Chenchen Qian; Dominik Bettenworth; Jie Wang; Jiannan Li; David H Bruining; Vipul Jairath; Brian G Feagan; Min-Hu Chen; Florian Rieder
Journal:  Physiol Rev       Date:  2021-09-27       Impact factor: 37.312

Review 6.  B cell class switching in intestinal immunity in health and disease.

Authors:  Aaron Fleming; Tomas Castro-Dopico; Menna R Clatworthy
Journal:  Scand J Immunol       Date:  2022-01-12       Impact factor: 3.889

Review 7.  Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature.

Authors:  Weixun Zhou; Yan Huang; Jinping Lai; Jun Lu; Michael Feely; Xiuli Liu
Journal:  Gastroenterology Res       Date:  2018-05-31

Review 8.  Crohn's Disease Following Rituximab Treatment for Follicular Lymphoma in a Patient with Synchronous Gastric Signet Ring Cells Carcinoma: A Case Report and Literature Review.

Authors:  Elisabetta Cavalcanti; Raffaele Armentano; Ivan Lolli
Journal:  Cancer Res Treat       Date:  2020-07-13       Impact factor: 4.679

Review 9.  Rituximab-induced Ileocolitis in a Patient with Gastric MALToma: A Case Report and Literature Review.

Authors:  Yoshikazu Tsuzuki; Rie Shiomi; Keigo Ashitani; Kazuya Miyaguchi; Atsushi Osaki; Hideki Ohgo; Rei Kim; Atsushi Sasaki; Taketo Yamada; Yoshitaka Miyakawa; Hidetomo Nakamoto; Hiroyuki Imaeda
Journal:  Intern Med       Date:  2021-03-01       Impact factor: 1.271
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.